First patient treated in phase 3 studies and positive Phase 2 results of roxadustat in patients with chronic kidney disease in Japan

News Hour:

Astellas Pharma Inc. (TSE:4503, “Astellas”) and FibroGen, Inc. (“FibroGen”),  announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney disease (CKD), which triggered a $10 million milestone payment from Astellas to FibroGen.

The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis. In the Phase 2 studies in Japan of CKD patients receiving dialysis and not receiving dialysis, roxadustat was well tolerated and met the primary objective of demonstrating dose-related rates of hemoglobin (Hb) increase measured over the first six weeks of treatment, as well as anemia correction and Hb maintenance over the 24-week treatment period.

 

“Anemia is a common consequence of CKD and contributes to the poor quality of life associated with this disease,” said Dr. Bernie Zeiher, President, Development of Astellas. “We are pleased to advance roxadustat to Phase 3 studies in Japan, as a potential new oral treatment of anemia in CKD patients.” “We are encouraged by accumulated results showing roxadustat’s potential to be effective in treating anemia and well tolerated in Phase 2 clinical studies around the globe in multiple types of CKD patients with anemia. We appreciate the strong support from patients and physicians with respect to the roxadustat clinical development program, and believe roxadustat has the potential to improve the care of CKD patients with anemia,” said Thomas B. Neff, Chief Executive Officer of FibroGen.

Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Song about Bangabandhu to celebrate historic 7th March
The SARS-CoV-19 outbreak, a global threat
SMUCT GDM department organized first photography exhibition titled "Beautiful Bangladesh"
Saiful Huq, AAPM’s first Bangladesh-born president
Chinese video app Tik Tok banned in Indonesia for 'inappropriate content'

Advertisement

News of the Month

Scroll Up
%d bloggers like this: